Sanofi acquiring Dynavax for $2.2bn to expand adult vaccine portfolio
Listed global pharmaceutical company Sanofi has agreed to acquire infectious diseases vaccine specialist Dynavax Technologies for $2.2bn. The transaction marks a strategic push to dominate the underpenetrated adult vaccination market and diversify beyond a flu-heavy portfolio. The deal, priced at a 39% premium over Dynavax’s closing price on December 23, 2025, brings Sanofi immediate access to HEPLISAV-B, the only two-dose…
GTCR Acquires Zentiva from Advent in $4.8bn Deal
Global private equity firm Advent International has agreed to sell Czech generics leader Zentiva to Chicago-based private equity firm GTCR for €4.1bn, marking one of Europe’s largest healthcare transactions of 2025 and underscoring robust investor appetite for stable pharmaceutical assets. Advent acquired Zentiva from Sanofi in 2018 for €1.9bn and exits at more than double the valuation, reflecting seven years of operational transformation. Under Advent, Zentiva doubled…